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1 Summary 
 
Prostate cancer is one of the leading causes of cancer related deaths in males 
worldwide. Therefore there is a vast interest in trying to understand the exact 
reasons for this disease. In the last years several studies were able to expose 
more and more of the molecular mechanisms underlying prostate cancer. 
However, there are still a lot of areas which remain a black box. One of these is 
the correlation of inflammation and prostate tumor development. While there are 
several hints and hypotheses regarding this correlation, a lot of additional work 
is needed to finally be able to decipher this mechanism. This study is one 
further step in this direction. 
We used a mouse model expressing a constitutively active IKK2 in the prostate. 
IKK2 is a key mediator in the NFκB pathway and its constitutive activation leads 
to a permanent inflammatory signaling. Interestingly inflammatory signaling 
alone is not enough for the transformation of the prostate. However, in 
combination with the heterozygous knockout of the tumor suppressor PTEN 
inflammatory signaling does lead to tissue transformation and an increased 
proliferation. 
Real time RT PCR experiments revealed several up- and downregulated genes. 
Especially the expression of specific cytokines and chemokines seemed to be 
severely altered in the double transgenic mouse model. We reasoned that these 
chemokines were responsible for the infiltration of immune cells into the 
prostatic tissue. We detected these immune cells by additional 
immunohistochemical stainings. 
 
 
 
  
- 5 - 
 
Furthermore, we discovered the downregulation of smooth muscle cell markers 
and a resultant loss of smooth muscle throughout the epithelium. This is a 
known finding in prostate cancer and is usually correlated with tumor invasion, 
which, however, did not develop in our model. Therefore the loss of smooth 
muscle apparently is not enough to promote tumor invasiveness. 
All in all, this study gives some new insights into how inflammation could 
promote prostate tumor formation when combined with a tissue with a 
neoplastic transformation. 
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2 Zusammenfassung 
 
Prostatakrebs ist eine der führenden Todesursachen von an Krebs erkrankten 
Männern weltweit. Deshalb herrscht reges Interesse daran, die exakten 
Hintergründe dieser Krankheit zu erforschen und verstehen. Obwohl in den 
vergangenen Jahren verschiedene Studien immer mehr Details über die 
molekularen Mechanismen ans Licht bringen konnten, verbleiben viele 
Vorgänge unverstanden. Einer dieser Vorgänge ist der Zusammenhang 
zwischen Entzündung und der Entwicklung von Prostatakrebs. Mit dieser Studie 
wollen wir dazu beitragen, die unzähligen Vermutungen und Hypothesen dieser 
Korrelation zu bestätigen oder zu widerlegen. 
In diesem Projekt haben wir dazu mit einem Mausmodell gearbeitet, das ein 
konstitutiv aktiviertes IKK2 im Prostatagewebe aufweist. IKK2 spielt im 
Signalweg von NFκB eine zentrale Rolle und seine konstitutive Aktivierung führt 
zu einer andauernden Entzündungsreaktion. Diese Entzündungsreaktion alleine 
reicht allerdings nicht aus, um zu einer Transformation der Prostata zu führen. 
Erst in Kombination mit einem heterozygoten knock out des Tumor Suppressors 
PTEN kommt es zu einer Transformation der Prostata und zu einer erhöhten 
Proliferationsrate. 
Real time RT PCR Experimente enthüllten einige hinauf, bzw. hinunter 
regulierte Gene im doppelt transgenen Mausmodell. Bei vielen davon handelte 
es sich um Cytokine und Chemokine. Wir schlussfolgerten, dass diese 
Chemokine für die Infiltration des Gewebes durch Immunzellen, die wir mit 
mittels immunohistochemischen Stainings sichtbar machen konnten, 
verantwortlich zeichneten. 
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Desweiteren entdeckten wir eine drastische Hinunterregulierung von 
sogenannten „smooth muscle cell markers“ und eine daraus resultierende 
Abnahme von glatter Muskulatur im Epithel. Diese Reduktion von glatter 
Muskulatur ist ein bekanntes Phänomen und korreliert normalerweise mit einem 
invasiven Charakter des Tumors. Interessanterweise entwickelte sich in 
unserem Modell kein invasiver Phänotyp, was darauf schließen lässt, dass das 
Verlorengehen von glatter Muskulatur alleine nicht ausreicht, um zu einem 
invasiven Tumor zu führen. 
Alles in allem bietet diese Studie neue Einblicke in die Zusammenhänge von 
Entzündung und Prostatakrebsentstehung in einem bereits neoplastisch 
transformierten Gewebe. 
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3 Introduction 
 
3.1 Anatomy of the prostate gland 
 
Generally the prostate consists of several epithelial glands and a fibromuscular 
stroma. Three different types of cells can be found in this glandular epithelium: 
basal, luminal secretory and neuroendocrine cells. The role of the basal cells is 
not fully understood yet but they seem to secrete certain components of the 
basement membrane and a specific subset of these cells might be epithelial 
stem cells. The luminal cells are responsible for the production of components 
of the prostatic fluid, expression of the androgen receptor and secretion of 
prostate – specific antigen (PSA) in an androgen – dependent manner. (1) 
The stroma consists of fibroblasts, smooth muscle cells, endothelial cells, 
dendritic cells, nerves and some infiltrating immune cells. Some stromal cells 
are responsive to androgen and produce growth factors, which in turn interact 
with the epithelial cells in a paracrine fashion. This stromal – epithelial 
interaction plays a very important part in the development and maintenance of 
the prostate. (2) 
While the mouse and human prostate are similar in histological organization, 
there are some significant differences. The murine prostate is assembled by 
four different lobes: the dorsal, lateral, ventral and anterior lobe. In comparison, 
the human prostate does not feature four distinct lobes but three different 
zones: the central, peripheral and transitional zone. (Figure 1) Notably, around 
70% of human prostate cancers arise in the peripheral zone. (3) 
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Figure 1: Comparison of a mouse (left) and a human (right) prostate. Source: (3) 
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3.2 Cancer 
 
Cancer is the leading cause of death in the Western world and the second 
leading cause of death in developing countries. Estimates for the year of 2008 
add up to 12,7 million cancer cases and 7,6 million cancer deaths worldwide. 
Breast cancer is the most frequently diagnosed cancer and the leading cause of 
cancer death in females, both in developed and developing countries. Prostate 
cancer is the most prevalently diagnosed cancer among males in developed 
countries and the third leading cause of cancer related death. In developing 
countries prostate cancer ranges on fifth place both in incidence and cancer 
related death. This results in prostate cancer being the second most commonly 
diagnosed cancer and the sixth leading cause of cancer related death in males 
worldwide. (4) 
In agreement with the above data prostate cancer is the most frequently 
diagnosed cancer in Austria, accounting for around 24% of diagnosed cancer 
incidences per year. Since the 1980ies prostate cancer was on a steady rise, 
which peaked in 2004 with nearly 5700 reported cases. The dramatic increase 
in the 1990ies can be explained by the massive implementation of PSA – 
screens, which have been performed on a regular basis since then. The 
mortality rate of prostate cancer in Austria was decreasing slightly since 2000 
after remaining at a steady state for the past decade. (5) 
 
3.2.1 The hallmarks of cancer 
 
Tumorigenesis is a multistep process evolving over many years. Thousands of 
different aberrant genes have been documented in different cancer tissues in 
the past, which demonstrates the complexity of this disease. 
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So far, it was believed that only six essential alterations in cell physiology were 
sufficient to collectively lead to malignant growth: self-sufficiency in growth 
signals, insensitivity to growth-inhibitory signals, evasion of programmed cell 
death, limitless replicative potential, sustained angiogenesis and tissue invasion 
and metastasis. (6) However, in the last few years several studies indicate an 
increasingly important seventh player in tumorigenesis: inflammation. (Figure 2) 
(6,7) 
 
 
 
Mitogenic growth factors are a requirement for the proliferative activity of normal 
cells. Tumor cells on the other hand are far more independent from exogenous 
growth factors. This leads to the conclusion that tumor cells must be able to 
produce their own growth factors and thereby reduce the dependency on the 
cellular microenvironment. This is achieved by oncogenes feigning normal 
growth signaling in several different ways. (6) 
 
Figure 2: The hallmarks of cancer. Source: (6) 
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Under normal circumstances antiproliferative signals are responsible for the 
maintenance of cellular quiescence and tissue homeostasis. If cancer cells are 
to expand they have to elude these growth inhibitors. Reactivity to antigrowth 
factors is closely linked to the G1 phase of a cell’s growth cycle. The 
retinoblastoma protein (pRb) pathway plays a major role in the progression from 
G1 into S phase and thus the disruption of this pathway leads to insensitivity to 
antigrowth factors. This can be achieved in various ways, for example, by 
downregulation of the receptors of a signaling molecule or the expression of 
aberrant receptors. (6,8) 
Damaged or otherwise aberrant cells typically undergo programmed cell death 
in a normal tissue in order to prevent them from causing any damage. In order 
to grow tumor cells must not only be able to proliferate independently of the 
cellular environment, they also have to avoid apoptosis. The most commonly 
found way in tumors to acquire resistance to apoptosis is the mutation of the 
tumor suppressor p53, which plays an important role in the DNA damage 
sensor machinery that can induce apoptosis. (6) 
Interestingly, self – sufficiency in growth signals, insensitivity to growth inhibitors 
and evasion of apoptosis is still not enough for a tumor to develop. Most of the 
mammalian cells exhibit certain mechanisms which prevent cells from dividing 
endlessly. For example, with each completed replication cycle the telomeric 
ends of a chromosome shorten which makes it necessary to limit the number of 
possible cell divisions. If replication continues the ends of the chromosome 
cannot be protected anymore and the cell dies. To counter this, the most 
commonly found mechanism in tumors cells is the upregulation of the 
telomerase enzyme. (6,9) 
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Furthermore, for any cell to survive it needs to be supplied with oxygen and 
nutrients. This is the responsibility of the vasculature, whose development is 
tightly regulated. In order for a tumor to be able to keep growing it has to induce 
and sustain angiogenesis. To this end tumors activate an angiogenic switch by 
interfering with the balance of angiogenic inducers and inhibitors. (6) 
These five hallmarks of cancer are not only required for a primary tumor to grow 
and survive but also for successful tumor invasion and metastasis, which 
constitutes the sixth hallmark of cancer and can be held responsible for around 
90% of human cancer deaths. (6,10) 
As already mentioned above, nowadays inflammation is considered the seventh 
hallmark of cancer. Nearly all cancer types can be associated with inflammation 
in one way or another. However, the exact role inflammation plays in cancer 
development and progression seems to be very complex and is still subject of 
extensive study. (7,10) 
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3.3 Prostate Cancer 
 
As previously stated prostate cancer is one of the leading causes of cancer 
related deaths worldwide. Just like any other type of cancer, prostate cancer is 
subject of aforementioned conditions. 
 
3.3.1 Genes involved in prostate cancer 
 
Recent studies have identified the most commonly altered genes in prostate 
cancer. These include, but are not limited to, AR, PTEN, Nkx3.1 and TP53. 
(Figure 3) (11,12) 
 
 
 
 
 
 
 
 
 
Figure 3: The most commonly mutated or epigenetically altered genes found 
in prostate cancer. Percentages indicate the frequency of appearance in 
different stages of the disease. Source: (11) 
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3.3.1.1 Androgen Receptor (AR) 
 
All types of cancer depend on increased cell proliferation and reduced cell 
death in order to be able to grow. In the prostate androgens are responsible for 
the regulation of the proportion of cell proliferation and apoptosis by, on the one 
hand, activating proliferation and on the other hand repressing apoptosis. The 
main circulating androgen is testosterone, which is converted into the more 
active dihydrotestosterone (DHT) upon arrival in the prostate. DHT has a 
fivefold higher affinity to the androgen receptor. Testosterone and DHT bind to 
the AR in order to induce transcriptional activity. This process is regulated by 
interaction of AR with coregulators and by phosphorylation of AR or the 
cofactors in response to various growth factors. (6,2) 
A functional AR is required for the initial development of the prostate as AR 
knockout experiments have shown. After the development of the prostate 
androgens and AR are important for the maintenance of the secretory epithelia, 
by balancing cell survival and death. Approximately 80-90% of prostate cancers 
are dependent on androgen at initial diagnosis. Interestingly, at some point in 
prostate cancer formation an androgen independency arises. AR expression, 
however, persists throughout prostate cancer progression. This is an important 
point as a very commonly used treatment against prostate cancer includes 
androgen ablation therapy. Studies have shown that AR mutations are rather 
rare in untreated prostate cancers. Therefore it has been suggested that other 
signaling pathways are interacting with AR and thus promoting carcinogenesis. 
Moreover it is hypothesized that an altered gene expression of the various 
coregulators of AR plays an important role in prostate tumorigenesis. (2) 
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3.3.1.2 Phosphatase and Tensin Homolog (PTEN) 
 
The tumor suppressor gene PTEN has been found to be frequently mutated in 
glioblastoma, breast and prostate cancers. PTEN is a lipid phosphatase that 
removes the 3 – phosphate from 3 – phosphorylated inositol lipids. These lipids 
function as second messengers that lead to the activation of the protein kinase 
AKT or protein kinase B (PKB). AKT is known to phosphorylate and inactivate 
several proapoptotic genes, which is important for the balance of cell 
proliferation and death. Thus, by mutating PTEN and therefore activating the 
AKT pathway cells are able to avoid apoptosis. Moreover, AKT has also been 
shown to be involved in cell cycle progression. (11) 
 
3.3.1.3 NKX3.1 
 
The human homeobox gene NKX3.1 is required for normal development of the 
human prostate, where it is heavily involved in the formation of the prostatic 
epithelium. Furthermore it is needed for normal prostate function as null 
mutants display defects in ductal morphogenesis and secretory protein 
production. NKX3.1 also regulates the proliferation of the prostate epithelium. 
Loss of NKX3.1 is frequently detected in human prostate cancer and has been 
associated with hormone – refractory disease and advanced tumor stage. 
(11,12) 
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3.3.1.4 TP53 
 
The tumor suppressor gene TP53 encodes for the tumor suppressor gene p53, 
which is heavily involved in the regulation of the cell cycle. P53 is the most 
frequently mutated gene in human cancers. (11) 
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3.4 Inflammation 
 
Generally, inflammation is an elementary immune response that is important 
during injuries or infections. Under these circumstances inflammation can 
secure survival and maintain tissue homeostasis. The downside of inflammation 
is, however, that it can lead to a transient decline in tissue function, which in 
turn can contribute to the pathogenesis of various diseases. (13) 
Typically, an inflammatory response is made up by inflammatory inducers, 
sensors, inflammatory mediators and the target tissue. The number of possible 
players of an inflammatory response is huge and strongly depends on the type 
of infection or injury. For example, while bacterial infections lead to a 
macrophage induced production of certain chemokines (CCL2, CXCL8) and 
cytokines (TNF, IL-1, IL-6) and viral infections lead to the production of type – I 
interferons (IFN-α, IFN-β) by the infected cells, infections with parasitic worms 
lead to the production of different cytokines (IL-4, IL-5, IL-13) by mast cells. All 
these mediators have a different impact on the course of the inflammatory 
response and on the subsequent activation of associated signaling pathways. 
(14) 
 
3.4.1 NFκB 
 
NFκB plays a central role in basically all types of inflammation. Moreover, NFκB 
activity can be detected in many different types of cancer. Generally, these 
transcription factors regulate the balance between cell survival and death and 
play a role in the regulation of cell proliferation and differentiation. 
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NFκB belongs to the rapid acting primary transcription factors. It is present in 
cells in an inactive state at all times and can be activated without the need for 
protein synthesis. This is achieved by IκB binding to NFκB in the cytoplasm and 
thus inactivating it. In order to activate NFκB, IκB needs to be degraded. To this 
end IκB is phosphorylated by either of the two kinases IKKα or IKKβ. The 
binding of certain cytokines, such as IL-1 or TNFα leads to the activation of 
these kinases via certain adapter molecules. Once IκB is degraded, NFκB can 
move into the nucleus and impact gene expression. (Figure 4) (14,15) 
 
 
 
 
 
 
 
Figure 4: Activation of NF-κB and subsequent induction of several downstream elements playing 
an important role in tumorigenesis. Source: (14) 
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3.5 Cancer & Inflammation 
 
Inflammation is a very complex disease featuring many different causes, 
mechanisms, outcomes and intensities. Consequently, different types of 
inflammation can promote cancer development and progression in different 
ways. 
There are two pathways linking inflammation and cancer: an extrinsic and an 
intrinsic pathway. The extrinsic pathway is distinguished by inflammatory 
conditions that increase cancer risk, while the intrinsic pathway is branded by 
genetic alterations that lead to inflammation and subsequently neoplasia. In the 
end, both pathways converge and lead to the activation of some consequential 
transcription factors, mainly NFκB, STAT3 and HIF1α. These transcription 
factors are responsible for the expression of inflammatory mediators, which in 
turn lead to cancer – related inflammation via various mechanisms. (Figure 5) 
(16) 
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Figure 5: Two pathways link inflammation and 
cancer: the intrinsic and extrinsic pathway. While 
they are activated by different causes, they 
subsequently converge, resulting in the activation of 
certain transcription factors. This results in the 
induction of specific cytokines and chemokines and 
in the end in cancer related inflammation with severe 
implications on tumor development. Source: (16) 
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The correlation of various infections and specific types of cancer is well 
documented. Generally, an infection leads to an immediate inflammatory 
response as part of the normal defense system of the host. Unfortunately 
however, tumorigenic pathogens are able to form persistent infections. These 
infections go along with chronic inflammation which in turn favors tumor 
development and progression. Another cause of chronic inflammation can be 
immune deregulation and autoimmunity. (10) 
Furthermore, several studies have shown that the exposure to environmental 
factors such as tobacco smoke, which can be linked to lung cancer, or asbestos 
or even obesity plays a huge role in tumor formation and progression, as it can 
also lead to chronic inflammation. (10,17) 
All these types of inflammation precede and promote tumor formation in one 
way or another. In contrast, there is also inflammation that follows tumor 
development, constituting a protumorigenic microenvironment. This can be 
induced by certain oncogenes, such as RAS and MYC, whose activation leads 
to an alteration of the tumor microenvironment through the recruitment of 
leukocytes and lymphocytes, expression of tumor – promoting cytokines and 
chemokines and induction of an angiogenic switch. Furthermore, if a tumor is 
lacking oxygen or nutrients necrotic cell death will occur at its core. This leads 
to the release of pro – inflammatory mediators, which in turn promotes neo – 
angiogenesis and facilitates additional growth factors for the tumor cells. (10,16) 
Moreover, some tumors are able to produce an inflammatory microenvironment 
by actively secreting certain molecules, such as IL1β. 
Interestingly, cancer therapy can be another strong elicitor of tumor associated 
inflammation. Both radiation and chemotherapy lead to a huge amount of 
necrotic cell death, which in turn results in an inflammatory response, as 
already mentioned above. (10) 
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Due to inflammation the tumor microenvironment consists of both cells of the 
innate and adaptive immune system, apart from cancer cells and the encased 
stroma. Distinct communication of these different cell types with each other is 
essential for the maintenance of tumor growth. They can either interact directly 
or via the expression of cytokines and chemokines. This composition of immune 
modulators and the state of activation of different cell types is exactly what 
makes the distinction between tumor promoting inflammation and anti tumor 
immunity.  
Many cells found in the microenvironment have both tumor promoting and 
inhibiting properties. The most commonly found cells are tumor associated 
macrophages (TAMs). TAMs generally promote tumor growth and stimulate T – 
cells, which can be divided into various subsets with different consequences on 
said tumor growth. Interestingly, similar T – cell subsets may act pro – 
tumorigenic in one and anti – tumorigenic in another type of cancer. The exact 
reasons for this still remain unknown and will need to be elucidated in the 
future. (10,18) 
However, probably more important than the actual composition of immune cells 
in the tumor microenvironment is the chemokine and cytokine expression 
profile. Cytokines lead the activation of different downstream regulators, such 
as NFκB, STAT, AP-1 or SMAD, regardless of their source. Therefore they 
control the immune and inflammatory milieu to either lead to the formation of a 
microenvironment favoring anti – tumor immunity or endorse tumor progression. 
Moreover, certain cytokines can also have direct influence on cell growth and 
survival.  (10) 
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3.5.1 Tumor initiation 
 
The role of inflammation in tumor initiation is again not clearly elucidated yet. 
Tumor initiation starts with a single mutation which provides a cell with survival 
advantages and is typically followed by additional mutations. The cause of this / 
these mutation(s) might be found in environmental mutagens but there is also 
the possibility that inflammation is much more critical in this process than 
previously anticipated. On the one hand activated inflammatory cells constitute 
a source of reactive oxygen species (ROS) and reactive nitrogen intermediates 
(RNI), which can both lead to DNA damage. On the other hand it would also be 
possible that immune cells utilize specific cytokines to excite an aggregation of 
ROS. (6,10) 
Furthermore, inflammation induced mutagenesis might lead to the inhibition of 
mismatch repair enzymes and subsequently the inactivation of important tumor 
suppressors. 
The upregulation of the enzyme AID (activation – induced cytidine deaminase), 
which is known to be up regulated in many cancers, is another possibility to 
associate inflammation with oncogenic mutations. AID promotes 
immunoglobulin gene class switching and its production either induced by 
inflammatory cytokines in an NFκB dependent manner or TGFβ. AID expression 
leads to an increased genomic instability and mutation chance. (10,19) 
Several alternatives have been proposed in the past years how inflammation 
could correlate with tumor initiation. There have been hints, for example, that 
inflammation induced epigenetic mechanisms might play a role in tumor 
initiation in one way or another. Another proposed mechanism includes copying 
a stem cell like phenotype on progenitor cells or exciting stem cell expansion by 
the production of certain growth factors and cytokines. (10) 
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3.5.2 Tumor promotion 
 
There are many different ways how inflammation can affect tumor promotion. 
Certain chemokines and cytokines, produced by immune and inflammatory cells 
play a very important role in tumor promotion. These tumor promoting cytokines 
lead to the activation of certain transcription factors, such as NFκB, STAT3 and 
AP-1 which in turn results in the induction of genes for cell proliferation and 
survival. The target genes of these transcription factors exerting tumor 
promoting functions are numerous and still subject of study. 
Tumor promoting cytokines might also be very important for the promotion of 
angiogenesis in hypoxic regions. There have been hints that hypoxic stimuli 
might generate inflammatory signals, which in turn promote angiogenesis. This 
would be supported by the fact that many pro – angiogenic genes are under 
direct control of NFkB, STAT3 and AP-1 in TAMs and other cell types. (10) 
 
3.5.3 Metastasis 
 
Over 90% of cancer deaths can be accounted to metastasis. Recent studies 
have shown that successful metastasis depends on distinct cooperation 
between cancer and inflammatory cells, as well as stromal elements. (6,10) 
Generally, four major steps are required for the process of metastasis. First, 
cancer cells need to acquire fibroblastoid characteristics, which lead to an 
increased mobility and the ability to invade epithelial membranes. To this end 
they need to undergo epithelial – mesenchymal transition (EMT). An important 
regulator of EMT and metastasis is TGFβ, whose function is quite diverse in a 
tumor microenvironment and seems to be tightly regulated. Other regulators of 
EMT are Twist and Kiss, whose transcription is activated by STAT3 and NFκB 
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signalling. Snail, a repressor of E – Cadherin is stabilized in the presence of 
TNFα and therefore constitutes another important player in EMT. (10,20) 
Secondly, cancer cells intravasate into blood vessels. This step might be driven 
by inflammation and the production of certain mediators, which increase 
vascular permeability. For example, IL-1, TNFα and IL-6 seem to promote 
invasiveness by NFκB and STAT3 mediated expression of certain matrix 
metalloproteinases (MMP), which are essential for the degradation of the 
extracellular matrix. In prostate and breast cancers accumulation of activated 
IKKα is related to reduced expression of maspin, which is a known inhibitor of 
metastasis. The exact nature of this mechanism, however, is not yet fully 
understood. (10,21) 
Thirdly, the metastasis initiating cells surviving the preceding steps start to 
travel throughout the circulation. Specific inflammatory mediators, such as 
TNFα and IL-6, are required for these cells to survive in suspension and resist 
detachment – induced cell death. On the one hand they lead to NFκB and 
STAT3 activation, on the other hand some cytokines are also able to physically 
link cancer cells to TAMs, resulting in them travelling together throughout the 
circulation. Moreover, this link also provides a certain protection from the 
immune system. 
The final step is represented by single metastatic progenitors interacting with 
local inflammatory and stromal cells and starting to proliferate. Systemic 
inflammation alleviates the attachment of circulating cancer cells to certain 
tissues, as several proinflammatory cytokines lead to an upregulation of the 
expression of certain adhesion molecules. (10) 
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3.6 Inflammation and prostate cancer 
 
People suffering from chronic prostatitis are known to have an increased 
chance of developing prostate cancer at some point. The postulated precursor 
of prostate cancer is high – grade prostate intraepithelial neoplasia (HGPIN), 
which in turn some researchers believe to develop from proliferative 
inflammatory atrophy (PIA). Interestingly, the atrophic epithelial cells in PIA 
show increased proliferation compared to normal cells. Moreover, PIA, HGPIN 
and carcinoma feature several similar molecular and genetic changes, such as 
chromosome 8 abnormalities, p53 mutations, an increased level of Bcl-2 protein 
and downregulation of PTEN. Furthermore, morphological studies have come to 
the conclusion that there is a direct transition between PIA, HGPIN and 
carcinoma. All this leads to the conclusion that the atrophic epithelial cells in 
PIA might be the target of neoplastic transformation and thus induce carcinoma 
formation either directly or indirectly via HGPIN development. (22,23) 
In most prostate cancer incidents the exact cause of inflammation remains 
unknown. As previously illustrated, the potential causes range from direct 
infection and dietary factors to an autoimmune reaction or – specific for the 
prostate – urine reflux. (10,23) 
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3.7 Aim of the study 
 
As already mentioned prostate cancer is the most frequently diagnosed cancer 
in males in the Western world and is also on the rise in developing countries. It 
is one of the leading causes of cancer related deaths worldwide. Although 
several theories about the exact mechanisms behind this disease have been 
proposed so far, there is still a lot of work to do to validate or falsify these 
hypotheses. 
In the last years inflammation has been confirmed to play an important role in 
various cancer types and is considered a hallmark of cancer by now. There is a 
growing amount of evidence that inflammation is also needed for the 
development and progression of prostate cancer. It is not only essential to 
elucidate the role of inflammation in order to finally understand the underlying 
causes of development and progression of prostate cancer but certain key 
players in inflammatory signaling could also constitute promising targets for anti 
cancer therapies. 
In this study we wanted to deepen our understanding of how inflammation can 
promote prostate tumorigenesis and possibly indentify new players involved in 
the process. To this end we used one transgenic mouse model, which featured 
a heterozygous knockout of the tumor suppressor PTEN in prostate epithelial 
cells and another one featuring a constitutively active IKK2. By crossing these 
two we received a double transgenic mouse model featuring PIN formation and 
thus the initial step of prostate tumor formation combined with an inflammatory 
microenvironment. Therefore, we were able to compare morphology and gene 
expression of certain genes of the double transgenic mice with mice carrying 
only the PTEN knockout and wildtype mice. This enabled us to investigate the 
impact of a chronic inflammation on tumor development in a prostate with 
neoplastic transformation.  
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Starting with simple HE stainings to illustrate the morphological changes in the 
genetically different prostates, we moved on to staining the tissues with specific 
immune and proliferation markers and studied the gene expression of selected 
genes via RT – PCR. 
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4 Results 
 
4.1 Strong stromal response in PTEN+/- IKK2ca/ca prostates 
 
The monoallelic deletion of PTEN leads to the development of prostatic 
intraepithelial neoplasias (PIN) late in mouse life. (24) We wanted to know if a 
constitutively active IKK2 signaling would influence this tumor formation and 
whether it would promote invasiveness. To this end we performed histological 
stainings using Hemalaun and Eosin. Hemalaun stains the nuclei and the ER 
blue while Eosin stains the cytoplasm and collagen fibers pink. These stainings 
revealed that wildtype tissue showed a normal epithelium while the PTEN+/- 
prostate had some hyperplasia and PINs. The epithelium of PTEN +/- 
IKK2ca/ca prostates emerged as much more hyperplastic but with the same 
amount of nuclear atypia as PTEN+/- mice. Interestingly the stroma of the 
double transgenic mice appeared to be highly altered. It clearly contained 
several collagen fibers compared to both wildtype and PTEN+/- mice. (Figure 1) 
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These data show that, apart from the appearance of hyperplasia and the 
formation of PINs, there is a strong stromal response in PTEN+/- IKK2ca/ca 
prostates compared to both PTEN+/- and wildtype prostates. This is an 
interesting finding as interactions between the epithelium and the stroma play 
an important role in prostate development and disease. 
 
4.2 Increased proliferation in PTEN+/- IKK2ca/ca mice 
compared to PTEN+/- and wildtype mice 
 
Aside from the strong stromal response and the occurrence of PINs we also 
found an increase in proliferation of both epithelial and stromal cells in PTEN+/- 
IKK2ca/ca mice compared to PTEN+/- and wildtype mice. 
Figure 3: Histological staining of PTEN+/- IKK2ca/ca, PTEN+/- and wildtype prostates; upper 
panel: the epithelium of a PTEN+/- IKK2ca/ca prostate appears as severely hyperplastic 
compared to the PTEN+/- prostate, which is less hyperplastic, and the wildtype prostate. Lower 
panel: the stroma of the PTEN+/- IKK2ca/ca prostate appears highly altered containing 
numerous collagen fibers in comparison to the wildtype and PTEN+/- prostate. 
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Nuclear Ki67 is known to be solely expressed in proliferating cells and is 
therefore commonly used as a target for antibodies in cancer diagnostics to 
check for an increase in proliferation in different tissues. (25) Thus we stained 
different tissues with Ki67 antibody and counterstained with Hoechst. Hoechst 
binds to the minor grove of the DNA and therefore stains all cells. This is 
important in order to be able to eliminate false positive and background signals. 
While there is little to no positive Ki67 signal to be found in the PTEN+/- and 
wildtype prostates several positive signals are visible in the PTEN+/- IKK2ca/ca 
prostates indicating increased proliferation in this tissue. (Figure 2) 
 
 
 
 
 
One basic requirement for a tumor to be able to grow and prosper is the 
deregulation of cell proliferation. (26) Furthermore, being independent of growth 
signals and immune to anti – proliferative signals are two hallmarks of cancer. 
(6) To this end the increased proliferation in our PTEN+/- IKK2ca/ca mice is a 
very interesting thing to note. 
Figure 2: Immunofluorescence staining of PTEN+/- IKK2ca/ca, PTEN+/- and wildtype mouse 
prostate tissues with the proliferation marker KI67; arrows indicate positive signals; counter 
stained with Hoechst 
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4.3 Persistent Inflammation in PTEN+/- IKK2ca/ca prostates 
 
In addition to the increased proliferation in the epithelium and stroma of 
PTEN+/- IKK2ca/ca prostates and the general stromal response there were also 
clear signs of a severe prostatitis. Prostatitis is the histological inflammation of 
the prostate, which is indicated by the infiltration of the tissue by immune cells. 
One of the first cells to arrive at the target site are neutrophils. There their 
function spans from the recruitment of other immune cells to the isolation and 
elimination of pathogens. (27) The other quickly arriving type of immune cells 
are monoctyes. On the one hand monocytes can actively purge infected cells or 
pathogens and on the other hand they can differentiate into either dendritic cells 
or macrophages which in turn hold several different functions including 
phagocytosis. (28) 
To check for the presence of these cells we performed immunofluorescence 
stainings with CD11b, F4/80 and GR-1 antibodies. CD11b is a macrophage and 
monocyte specific antibody while F4/80 stains macrophages only and GR-1 
specifically binds to neutrophils. Again, we counterstained with Hoechst in order 
to be able to filter out any false positive signals. We were able to prove the 
presence of all of these three markers in our PTEN+/- IKK2ca/ca prostates. 
(Figure 3) 
 
  
- 34 - 
 
 
 
 
 
 
These data clearly show that there is a persistent inflammation going on in 
PTEN+/- IKK2ca/ca prostates. The constitutive activation of IKK2 in PTEN+/- 
prostates is enough to lead to severe inflammation. As inflammation has 
emerged as a very important player in cancer development and progression in 
the last years this mouse model appears to be perfect to study the connection 
between inflammation and prostate cancer. (7) 
 
Figure 3: Immunofluorescence staining of PTEN+/- IKK2ca/ca prostate 
tissues with the immune cell markers CD11b (monocytes & 
macrophages), F4/80 (macrophages) and GR-1 (neutrophiles); counter 
stained with Hoechst 
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4.4 Loss of smooth muscle in PTEN+/- IKK2ca/ca prostates 
 
To further investigate the reasons behind the changes in the stroma of PTEN+/- 
IKK2ca/ca prostates revealed by our histological stainings we next checked the 
expression of several stromal genes. Interestingly we found that the two smooth 
muscle cell markers smooth muscle myosin heavy chain (MYH11) and smooth 
muscle actin (SMA) were drastically downregulated in PTEN+/- IKK2ca/ca 
prostates compared to PTEN+/- and wildtype prostates. (Figure 4) 
 
 
Figure 4: quantitative RT – PCR comparing the expression level of MYH11 and SMA in 
PTEN+/- IKK2ca/ca, PTEN+/- and wildtype mouse prostate tissues. 
 
Expression levels of MYH11 were much lower in our double transgenic mice 
compared to the wildtype and PTEN+/- mice. The difference in the expression 
level of SMA was even more apparent when comparing these three genotypes, 
accentuated by a 40 to 80 fold downregulation. 
To further emphasize these results we also stained prostate tissues with the 
respective genotypes with SMA antibody. Smooth muscle Actin (red staining) 
continuously surrounds the prostatic ducts in the PTEN+/- and wildtype prostate 
tissues while there nearly is a complete loss thereof in the PTEN+/- IKK2ca/ca 
tissue. (Figure 5) 
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Myh11 mutations have been identified in human colorectal cancer and acute 
myeloid leukemia in the past. Generally Myh11 has been hypothesized to also 
play an important role in various other types of cancer which perfectly goes 
along with the data we received in our model. (29) 
Taken together these data confirm a drastic change in the stroma of PTEN+/- 
IKK2ca/ca prostates. These changes go along with a noticeable loss of smooth 
muscle. However, although the loss of smooth muscle is associated with an 
invasive phenotype in many tumor models, we did not find any indicator of an 
increased invasiveness in our model. 
 
4.5 PPM1A is down – regulated in PTEN+/- IKK2ca/ca mice 
compared to PTEN+/- mice. 
 
Another interesting gene we found, whose expression appeared to be altered 
was PPM1A. Nuclear PTEN is known to stabilize the Smad2/3 phosphatase 
PPM1A by establishing a complex with it. (30) 
Figure 5: Immunofluorescence staining for SMA (red) on PTEN+/- IKK2ca/ca, PTEN+/- and 
wildtype prostate tissues; counterstained with Hoechst (green) 
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PPM1A expression is slightly down – regulated in PTEN+/- IKK2ca/ca tissues 
compared to PTEN+/- and wild type tissues. (Figure 6) 
Since PPM1A is known to interact with PTEN this downregulation appears to be 
an interesting finding in our PTEN+/- IKK2ca/ca mouse. However, the exact role 
of this player and its possible impact on cancer formation and its association 
with inflammation in our mouse model still remains somewhat unclear and will 
need to be elucidated in the future. 
 
4.6 Ck18 expression levels are higher in PTEN+/- IKK2ca/ca 
epithelial cells compared to PE-PTEN+/- IKK2ca/ca stromal 
cells 
 
Epithelial – stromal interactions decisively influence the development and 
functionality of the prostate. Moreover they play a very important role in various 
derangements of the prostate glands, such as BPH and prostate carcinoma. 
Figure 6: quantitative RT – PCR comparing the expression level of 
PPM1A in PTEN+/- IKK2ca/ca, PTEN+/- and wild type mouse 
prostate tissues 
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(31) In our PTEN+/- IKK2ca/ca prostates the genetic changes in the epithelium 
give rise to the inflammation of the whole prostate. For this reason we next 
wanted to check the gene expression of PTEN+/- IKK2ca/ca epithelial cells 
against PTEN+/- IKK2ca/ca stromal and wildtype cells. Therefore we produced 
both epithelial and stromal cell lines from a PTEN+/- IKK2ca/ca mouse prostate 
by explant cultures. 
 
 
 
 
Cytokeratin 18 is found in many epithelial tissues. It is hypothesized to have 
various functions, one being helping to maintain epithelial cell integrity. (32) 
Therefore CK18 antibodies are frequently used as markers for epithelial tissues 
in several organs. The CK18 expression in our epithelial cells is hundred fold 
increased compared to the stromal cells while Collagen I expression, which is a 
common marker for stromal tissues, is hundred fold increased in the stromal 
cells compared to the epithelial cells. (Figure 7) 
These data confirm that the cell lines we established were indeed a stromal and 
an epithelial cell line, respectively and therefore were perfectly suited to study 
the different gene expression and the implication diverse chemokines would 
have on these cell types. 
 
Figure 7: quantitative RT – PCR comparing the expression level of the epithelial marker CK18 
and the stromal marker Collagen 1 in PTEN+/- IKK2ca/ca stromal and PTEN+/- IKK2ca/ca 
epithelial cells 
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4.7 TNFα expression level is higher in PTEN+/- IKK2ca/ca 
epithelial cells compared to wildtype and PE-PTEN+/- 
IKK2ca/ca stromal cells 
 
TNFα, a cytokine heavily involved in inflammatory signaling, primary regulator of 
immune cells, known to play a role in, amongst other diseases, cancer and also 
known to be a target of NFkB, constituted an interesting target for us to check 
for an altered gene expression. (33) 
 
 
 
 
 
TNFα expression in both wildtype and PTEN+/- IKK2ca/ca stromal cells is about 
40 fold decreased compared to PTEN+/- IKK2ca/ca epithelial cells. (Figure 8) 
These data show that the constitutive activation of IKK2 in PTEN+/- prostates 
leads to an increased production of TNFα in the epithelium. This correlation 
between the altered gene expression in PTEN+/-IKK2ca/ca epithelial cells and 
the subsequently higher expression of TNFα plays an important role in the 
Figure 8: quantitative RT – PCR comparing the expression level of 
TNFα in PTEN+/- IKK2ca/ca epithelial and PTEN+/- IKK2ca/ca 
stromal and wildtype cells 
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recruitment of inflammatory cells and might explain the increased number of 
immune cells we have proven to infiltrate our PTEN+/- IKK2ca/ca prostates. 
 
4.8 CXCL15 and CXCL5 expression level is higher in PTEN+/- 
IKK2ca/ca epithelial cells compared to wildtype and PE-
PTEN+/- IKK2ca/ca stromal cells 
 
Generally, CXC chemokines are known to recruit all kinds of immune cells to an 
inflamed tissue and to be involved in the tumorigenicity of prostate cancer cells. 
(34) The production of some CXC chemokines can be induced by the 
stimulation of cells with inflammatory cytokines such as TNFα. (35) This is a 
very interesting point as we were able to prove that TNFα expression is strongly 
increased in the epithelium of PTEN+/- IKK2ca/ca cells. 
 
 
Figure 9: quantitative RT – PCR comparing the expression level of CXCL15 and CXCL5 in 
PTEN+/- IKK2ca/ca epithelial, PTEN+/- IKK2ca/ca stromal and wildtype cells 
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CXCL15 expression is many times higher in PTEN+/- IKK2ca/ca epithelial cells 
compared to both PTEN+/- IKK2ca/ca stromal and wildtype cells. CXCL5 is 
upregulated even more in the PTEN+/- IKK2ca/ca epithelial cells compared to 
both wildtype and PTEN+/- IKK2ca/ca stromal cells. (Figure 9) 
CXCL15 was first described in lung epithelial cells as a member of the CXC 
chemokine family with some peculiar properties. Its primary function is to recruit 
neutrophils during inflammation. (36) 
Similarly to CXCL15, CXCL5 is known to be an activator of the chemotaxis of 
neutrophils. (37) 
These data go in line with the increase of inflammatory cells found in the 
PTEN+/- IKK2ca/ca tissue. The increased production of both CXCL15 and 
CXCL5 might explain the increase of immune cells, especially neutrophils, in 
our PTEN+/- IKK2ca/ca prostate tissue. 
 
4.9 Changes in mRNA expression level of CXCL2 and CXCL10 
in PTEN+/- IKK2ca/ca stromal cells after treatment with 
TNFα 
 
Above, we were able to prove that TNFα expression and the expression of 
certain CXC chemokines in PTEN+/- IKK2ca/ca epithelial cells was a multiple of 
the expression in wildtype cells and stromal cells of the same genotype. 
Moreover, we could show that there is a strong increase of immune cells in 
PTEN+/- IKK2ca/ca mouse prostate tissues.  As already mentioned, epithelial – 
stromal interactions play an important role in the prostate and its diseases. 
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Considering all this, we wanted to prove the hypothesis that the stroma, 
activated by chemokines originating from the epithelium, was also able to recruit 
immune cells by the production of various chemokines. Therefore we next 
treated PTEN+/- IKK2ca/ca stromal cells with TNFα in order to see whether this 
treatment would lead to an altered gene expression in these cells, giving a 
further explanation for the increased number of immune cells in the stroma. 
 
 
Figure 10: quantitative RT – PCR of PTEN+/- IKK2ca/ca stromal cells after treatment with TNFα 
for 24h and 48h, respectively, comparing the gene expression of CXCL2 (A) and CXCL10 (B) 
with an untreated control 
 
Already after 24h the expression of CXCL2 in TNFα treated PTEN+/- IKK2ca/ca 
stromal cells is a multitude of the expression in the untreated control. After 
incubating the cells for another 24h, the expression levels approximately 
doubled. The same holds true for the expression of CXCL10. While there is no 
significant difference in its expression between the untreated cells and the cells 
incubated with TNFα for 24h, there is a boost of CXCL10 expression after 48h 
incubation. (Figure 10) 
CXCL2 is a small chemokine that is secreted by monocytes and macrophages. 
Its primary function is to recruit immune cells, more precisely granulocytes, to 
the target site. (38) 
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The CXC family member CXCL10 has been shown to have several functions 
such as inhibiting bone marrow colony formation and promoting T – cell 
adhesion to endothelial cells. But most importantly to us, it acts as a 
chemoattractant for monocytes. (39) 
Taken together these data clearly show that the stimulation of stromal PTEN+/- 
IKK2ca/ca cells with TNFα is enough to induce an increased production of both 
CXCL2 and CXCL10 in these cells. This, in turn, proves that the increased 
TNFα expression we detected in our epithelial cells has a huge impact on the 
gene expression of the two chemokines in the stromal cells. All this supports the 
hypothesis that the stroma, after being activated by cytokines from the 
epithelium, can express chemokines which in turn recruit immune cells. This 
clearly shows that the transgenic PTEN+/- IKK2ca/ca epithelium is able to 
recruit inflammatory cells by either direct or indirect production of chemokines. 
 
4.10 Changes in mRNA expression level of CXCL15 in PTEN+/- 
IKK2ca/ca stromal cells after treatment with TNFα 
 
As shown above CXCL15 was another member of the CXCL family we found to 
be upregulated in our PTEN+/- IKK2ca/ca epithelial cells compared to the 
PTEN+/- IKK2ca/ca stromal and wildtype cells. Therefore we wanted to see if 
incubation with TNFα would lead to an increased production of CXCL15 in the 
PTEN+/- IKK2ca/ca stromal cells, just as it turned out to be the case with 
CXCL2 and CXCL10 as shown before. 
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Interestingly, after treatment with TNFα the stromal cells did not show increased 
expression of CXCL15 but a strong decrease compared to the untreated 
control, totally in contrast to CXCL2 and CXCL10. (Figure 11) 
This is a somewhat interesting finding and will need to be adressed in the 
future. It could go in line with the fact that CXCL15 has some peculiar 
properties, as already mentioned above. Another possibility would be that TNFα 
alone is simply not sufficient to induce CXCL15 expression in our PTEN+/- 
IKK2ca/ca stromal cells but needs another co – factor. 
 
 
 
 
 
 
Figure 11: quantitative RT – PCR of PTEN+/- IKK2ca/ca stromal 
cells after treatment with TNFα for 24h and 48h, respectively, 
comparing the gene expression of CXCL15 with an untreated 
control 
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5 Materials & Methods 
 
5.1 Mice 
 
All mouse breeding, sacrificing and harvesting of organs was performed in 
cooperation with Dr. Andreas Birbach in accordance to institutional guidelines. 
 
5.1.1 Probasin-Cre mice 
 
Probasin-Cre mice were obtained from the National Cancer Institute – Frederick 
Mouse Respiratory. Since the Cre gene is under the control of the promotor 
ARR2PB, which is a derivative of the prostate – specific probasin (PB) 
promotor, this mouse line features a prostate – specific expression of the Cre 
recombinase. Originally Cre stems from the bacteriophage P1 and Cre – 
mediated excision of loxP elements is an essential tool for conditional gene 
activation or inactivation in molecular biology. (40,41) 
 
5.1.2 Mice with a floxed PTEN allele 
 
Mice with a floxed PTEN allele (PTENflox/-) were a gift from Prof. Tak Mak 
(Ontario Cancer Institute, Toronto, Canada). Crossing of these mice with 
Probasin-Cre mice leads to the excision of the floxed PTEN allele and therefore 
results in decreased levels of PTEN. (42) 
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5.1.3 R26StopFlIKK2ca mice 
 
R26StopFlIKK2ca mice were generated by Dr. Marc Schmidt-Supprian (Max 
Planck Institute for Biochemistry, Martinsried, Germany). After Cre-mediated 
deletion of the STOP cassette IKK2ca is expressed under control of the 
endogenous ROSA26 promotor in this strain. (Figure 1) (43) 
 
 
 
 
5.1.4 Mouse breedings and genoytpes used for this project 
 
The monoallelic deletion of PTEN alone is not enough to transform the prostate 
but leads to the development of PINs late in mouse life. (24) In order to be able 
to check whether an additional chronic inflammation of the prostate would lead 
to the successful transformation of the tissue we established three different 
mouse lines to compare gene expression and morphology. (Tab. 1) 
 
genotype 1 genotype 2 expected genotype in prostate epithelial cells 
Probasin-Cre R26StopFlIKK2ca IKK2ca/ca 
Probasin-Cre floxed PTEN allele PTEN+/- 
IKK2ca/ca floxed PTEN allele PTEN+/- IKK2ca/ca 
 
 
Figure 1: Scheme of the R26StopFlIKK2ca transgene. 
Source: (43) 
Table 1: Genetic background of the mice used in this study. (IKK2ca/ca; PTEN+/-; Pten+/-
IKK2ca/ca) 
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Subsequent analysis of the transgenic mice revealed that the expression level 
of the flagIKK2 transgene on a PTEN+/- background was highest in the lateral 
prostate. Therefore we used the lateral prostate lobe for all of the experiments 
in this study. 
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5.2 gDNA 
 
The respective genotype of each mouse used for this project was confirmed 
prior to commencing with the experiments. Therefore tail biopsies were taken 
immediately after sacrificing each mouse. The samples were stored in 500 µl 
lysis buffer with 3,0 µl Proteinase K (20 mg/ml) added and incubated at 58°C 
over night. 
 
5.2.1 gDNA isolation 
 
500 µl 5M NaCl was added to each of the previously incubated samples. After 
mixing they were centrifuged at 16000g at room temperature for 5 minutes. The 
supernatant was transferred to a new flask and carefully mixed with an equal 
volume of Isopropanol. Subsequently the samples were centrifuged at 16000g 
at room temperature for 30 minutes. After discarding the supernatant and 
adding 1 ml ice cold 70% Ethanol to each flask, the samples were centrifuged at 
16000g at room temperature for 5 minutes. Again the supernatant was 
discarded and the pellet was air dried for 10 minutes. Finally, the pellet was 
resuspended in 100 µl 10mM Tris pH8. 
 
5.2.2 Genotyping 
 
In order to verify the genotype of each sacrificed mouse we performed a 
Polymerase Chain Reaction (PCR) with the gDNA samples using four different 
primer pairs. (Tab. 2) 
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Gene / amplicon Primer sequence (sense / antisense) 
CRE 
5'-CGGTCGATGCAACGAGTGATGAGG-3' 
5'-CCAGAGACGGAAATCCATCGCTCG-3' 
PTEN 
5'-CTCCTCTACTCCATTCTTCCC-3' 
5'-ACTCCCACCAATGAACAAAC-3' 
rNeo/IKK2 
5'-GAGCTGCAGTGGAGTAGGCG-3' 
5'-GCCTTCTTGACGAGTTCTTC-3' 
Rosa26 
5'-CCAGATGACTACCTATCCTC-3' 
5'-GAGCTGCAGTGGAGTAGGCG-3' 
 
 
For the PCR 2,5 µl 10 x Buffer (Peq Lab, Erlangen, Germany), 0,5µl of each 
forward and reverse primer (10 µM), 0,5 µl dNTPs (10 mM), 0,1 µl Taq 
Polymerase (5 units/µl; Peq Lab) and 20 µl ddH2O were added to 1,0 µl of 
template DNA. The PCR was performed on an eppendorf thermocycler. 
(eppendorf, Hamburg, Germany) (Tab.3) 
 
Step Temperature Time Number of cycles 
Initiation 95°C 10 min 1 
Denaturation 95°C 30 sec 
35 Annealing 55°C 30 sec 
Elongation 72°C 1 min 
Final elongation 72°C 5 min 
1 
Storage 4°C ∞ 
 
 
The PCR products were loaded onto an agarose gel to check for the succesful 
or unsuccessful amplification of the respective genes. 
 
Table 2: List of primer sequences used for the PCR 
Table 3: PCR setup for genotyping 
  
- 50 - 
 
5.3 Cell Culture 
 
Most of the cell culture work was performed in collaboration with Dr. Andreas 
Birbach. 
5.3.1 Explant Culture 
 
Immediately after harvesting the prostate tissues were cut into small pieces of 
0,2 – 1,0 mm and put on collagenated tissue culture plates. A small amount of 
epithelial growth medium containing 1% serum was added and incubated at 
37°C for 24 hours. Once the tissues were attached to the plate more medium 
was added and then put back into the incubator for another 24 hours. Cells 
started to grow out from the prostate tissue after another 24 to 48 hours of 
incubation. In order to obtain either clean stromal or epithelial cell cultures the 
obverse cell type was removed with a cell scraper or pipette tip. (44) 
5.3.2 Cell Passaging 
 
The media was removed, cells were washed with 1xPBS and an appropriate 
amount of Trypsin EDTA or Accutase (PAA, Pasching, Austria) was added. 
Cells started to detach after a short incubation period (5 – 15 min). 
Subsequently the cells were transferred into a flask, centrifuged, resuspended 
and put back into the incubator. 
5.3.3 TNF treatment of cells 
 
An appropriate amount of TNF (20 ng/ml; Immunotools, Friesoythe, Germany) 
was added and cells were incubated for 24 to 48 hours, respectively. 
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5.4 RNA isolation 
 
Prior to any RNA related work the work bench and all used pipettes were 
cleaned to be made RNAse free. 
5.4.1 RNA isolation from prostate tissues 
 
Harvested prostate tissue was stored in RNAlater (Applied Biosystems, 
Carlsbad, USA). Tissues were homogenized using a Polytron Homogenizer. 
The RNA was purified on RNA binding columns using either RNeasy Mini Kit 
(Qiagen, Hilden, Germany) or peqGOLD Total RNA kit (Peqlab, Erlangen, 
Germany). The separate steps were performed according to the manufacturer’s 
instructions. 
5.4.2 RNA isolation from cells 
 
The medium was removed, cells were washed with 1 x PBS and 1 ml TRIZOL 
(Carl Roth GmbH, Karlsruhe, Germany) per 0,1 – 1,0 g of cells was added. The 
samples were transferred to flasks and incubated at room temperature for 5 – 
10 minutes. For complete disruption of the cells the samples were homogenized 
using a Polytron Homogenizer. 0,2 ml of chloroform for each 1 ml of TRIZOL 
used in the initial step was added. The samples were vortexed for 15 seconds 
and incubated at room temperature for 2 – 3 minutes. Then the samples were 
centrifuged at 12000g at 4°C for 15 minutes. The organic phase and the middle 
layer were discarded. The aquatic phase, which included the RNA, was 
transferred into a new flask and 0,5 ml Isopropyl alcohol was added for each 1 
ml of TRIZOL used in the initial step. After mixing, the samples were incubated 
at room temperature for 2 – 3 minutes. This was followed by another 
centrifugation step at 12000g at 4°C for 10 minutes. The supernatants were 
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removed and the pellets washed with 1 ml ice cold 75% Ethanol. The samples 
were then centrifuged at 7500g at 4°C for 5 minutes and the supernatants were 
discarded. The pellets were air dried for 5 – 10 minutes, resuspended in 10 µl 
RNAse free ddH2O and stored at -40°C. 
5.4.3 Measurement of RNA concentration 
 
RNA concentration was measured using UV spectometry. Therefore 1 µl of 
RNA was diluted in 100 µl of RNAse free ddH2O and 100 µl of RNAse free 
ddH2O alone served as blank. The absorbance was measured at 230 nm for 
contaminations, 260 nm for nucleic acid, 280 nm for protein and 320 nm for the 
background. 
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5.5 cDNA 
 
Original RNA samples were kept on ice at all times and after taking an aliquot 
thawed at -80°C again immediately. 
 
5.5.1 DNA digestion 
 
RNA was diluted in 8 µl RNAse free ddH2O to obtain a concentration of 0,1 
µg/µl. Then 1,0 µl of 10 x DNAseI buffer and 1 µl of DNAseI (Fermentas, St. 
Leon-Rot, Germany) were added and the samples incubated at 37°C for 30 
minutes. The DNAse digestion was stopped by incubating the samples at 75°C 
for 5 minutes. 
 
5.5.2 cDNA synthesis 
 
cDNA was synthesized using the RevertAid H Minus First Strand cDNA 
synthesis kit (Fermentas). The separate steps were performed according to the 
manufacturer’s instructions. Random hexamer primers were used. The 
produced cDNA was diluted in 40 µl of ddH2O and stored at -20°C. 
 
5.5.3 Quantitative Real time RT – PCR 
 
For the quantitative real time RT – PCR 2,5 µl 10 x buffer (Peq Lab), 2,375 µl 
DMSO (1:100 dilution), 0,125 µl SYBR Green (1:1000 dilution), 0,5 µl of each 
forward and reverse primer (10 µM) (Tab.4), 0,5 µl dNTPs (10 mM), 0,1 µl Taq 
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Polymerase (5 units/µl; Peq Lab) and 17,5 µl ddH2O were added to 1,0 µl of 
template cDNA. 
 
Gene / Amplicon Primer Sequence ( sense / antisense) 
Ck18 
5‘-CAGCCAGCGTCTATGCAGG-3‘ 
5‘-CTTTCTCGGTCTGGATTCCAC-3‘ 
Col1 
5’-CACCCTCAAGAGCCTGAGTC-3’ 
5’-GTTCGGGCTGATGTACCAGT-3’ 
CXCL2 
5‘-GCGCCCAGACAGAAGTCATAG-3‘ 
5‘-AGCCTTGCCTTTGTTCAGTATC-3‘ 
CXCL5 
5‘-GAAAGCTAAGCGGAATGCAC-3‘ 
5‘-GGGACAATGGTTTCCCTTTT-3‘ 
CXCL10 
5‘-GCTCCTGCATCAGCACCAGC-3‘ 
5‘-CTTGAACGACGACGACTTTGG-3‘ 
CXCL15 
5’-CCATGGGTGAAGGCTACTGT-3’ 
5’-TCTCAGGTCTCCCAAATGAAA-3’ 
HPRT 
5‘-CAAATCAAAAGTCTGGGGACGC-3‘ 
5‘-GCTTGCTGGTGAAAAGGACCTC-3‘ 
MYH11 
5‘-AAGCTGCGGCTAGAGGTCA-3‘ 
5‘-CCCTCCCTTTGATGGCTGAG-3‘ 
PPM1a 
5’-GCGGAGCTGGACAAGTACC-3’ 
5’-GCCTTCCACCTGCTTCTTTA-3’ 
SMA 
5‘-GTCCCAGACATCAGGGAGTAA-3‘ 
5‘-TCGGATACTTCAGCGTCAGGA-3‘ 
TNFα 
5‘-TAGCCAGGAGGGAGAACAGA-3‘ 
5‘-TTTTCTGGAGGGAGATGTGG-3‘ 
 
 
 
 
Table 4: List of primer sequences for the real time RT - PCR 
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The PCR was performed on a stepOne Plus Real – Time PCR cycler (Applied 
Biosystems). HPRT was used as normalization gene. To exclude false – 
positive signals a melting curve was established. (Tab.5) 
 
Step Temperature Time Number of Cycles 
Initiation 95°C 10 min 1 
Denaturation 95°C 15 sec 
40 Annealing 55°C 15 sec 
Elongation 72°C 1 min 
Final elongation 72°C 5 min 1 
 
 
Gene expression analysis was done using the StepOne Software v2.1 (Applied 
Biosystems). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5: Setup for quantitative real time RT - PCR 
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5.6 Tissue Sectioning 
 
5.6.1 Paraffin Sections 
 
First, the harvested tissues were fixed in 4% paraformaldehyd over night. 
Following this the tissues were dehydrated and embedded in paraffin in small 
tissue blocks. The samples were then cut into 2,0 µm sections using a Leica 
microtome (Leica Microsystems, Vienna, Austria) and collected on SuperFrost 
Plus slides (Thermo Scientific, Braunschweig, Germany). Sections were either 
processed directly or stored at room temperature for later use. 
 
5.6.2 Cryosections 
 
The harvested tissues were directly frozen in isopentane / liquid nitrogen and 
frozen at -80°C until cutting. The frozen tissues were cut into 8,0 µm sections 
using a cryostat and dried at room temperature for 20 minutes or longer. 
Sections were either processed directly or stored at -80°C for later use. 
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5.7 Stainings 
 
5.7.1 Slide Preparation 
 
5.7.1.1 Deparaffinization 
 
Paraffin sections were first deparaffinized two times in the xylol substitute 
Roticlear (Carl Roth) for 20 minutes and then rehydrated in descending ethanol 
solutions (100%, 96%, 80%, 70%, 50%) for 30 seconds each. Then the slides 
were incubated in ddH2O for 5 minutes. 
 
5.7.1.2 Antigen Retrieval 
 
Antigen retrieval was only necessary for formerly paraffinized slides. To achieve 
this, the slides were put in Antigen Retrieval Solution (Dako, Glostrup, 
Denmark) and brought to the boil in a microwave. The slides were simmered for 
20 minutes, cooled down to ambient afterwards and washed with 1 x PBS for 5 
minutes. 
 
5.7.1.3 Fixation of Cryosections 
 
Cryosections were incubated in ice cold acetone for 3 minutes, quickly air dried 
and washed in 1 x PBS for 5 minutes. 
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5.7.2 Histological staining 
 
Paraffin sections were used for all histological stainings. Rehydrated slides 
were incubated in Hemalaun (1:10 dilution; Carl Roth) for 5 minutes and 
adjacently carefully washed in running tap water for 5 minutes. Afterwards the 
slides were dipped into 1% HCl in 70% ethanol two times and immediately 
washed in running tap water for 7 minutes. Then they were incubated in an 
Eosin solution (2% Eosin in 70% Ethanol with a few drops of acidic acid added; 
Carl Roth) for 2,5 minutes and dehydrated in ascending ethanol solutions (80%, 
96%, 100%) for 30 seconds each. Finally, they were put into the xylene 
substitute for 1 more minute. After air drying the slides for 1 – 2 minutes they 
were mounted in Roti – mount (Carl Roth) and stored in the dark at room 
temperature. 
 
5.7.3 Immunostaining 
 
Tissues were encircled with a DakoPen (Dako) and blocked in 5% goat serum 
in 1 x PBS for 1 hour. The slides were incubated in a wet chamber with the first 
antibody in an appropriate dilution in 5% goat serum in 1 x PBS at 4°C over 
night. Then the samples were washed in 1 x PBS for 5 minutes 3 times and 
incubated in a wet chamber with the adequate secondary antibody in an 
appropriate dilution in 1 x PBS at room temperature for 1 hour. (Tab.6) 
Subsequently the slides were washed in 1 x PBS for 5 minutes 3 times and 
mounted in PBS / glycerol (1:7). Slides and cover slip were sealed with nail 
polish. 
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If using biotinylated antibodies samples were additionally treated with an Avidin 
/ Biotin blocking kit (Vector Laboratories, Burlingame, CA), prior to incubation 
with the primary antibody. Therefore the sections were incubated in Avidin for 
15 minutes and washed once in 1 x PBS for 5 minutes. Afterwards they were 
incubated in Biotin for another 15 minutes and then washed in 3 times 1 x PBS 
for 5 minutes each. 
If using fluorescent antibodies slides were protected from light by covering them 
with aluminum foil at all times. These slides were counterstained with Hoechst 
(stock: 1mg / ml; end conc.: 100ng / ml; diluted in 1 x PBS) for 5 minutes prior to 
the last washing step in 1 x PBS. 
Slides incubated with antibodies linked to HRP were evaluated using DAB 
tablets (Sigma-Aldrich, Vienna, Austria). The enzymatic reaction was observed 
under a light microscope and stopped with ddH2O at an appropriate time point 
but no later than 7 minutes after induction. Then the slides were counterstained 
in Hemalaun for 5 minutes and washed in running tap water for another 5 
minutes before they were sealed. 
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Antibody / Antigen Source (catalog # or 
equivalent) 
Use Dilution 
A555 goat anti rabbit Invitrogen A-21428 IF-P, IF-F 1:2000 
Biotin anti rabbit Vector Laboratories BA-1000 IHC-P 1:400 
Biotin anti goat Vector Laboratories BA-9500 IHC-P 1:400 
Biotin anti mouse Vector Laboratories BA-9200 IHC-P 1:400 
CD11b eBioscience 13-0112 IF-F 1:200 
F4/80 eBioscience 13-4801 IF-F 1:200 
Gr-1 eBioscience 13-5931 IF-F 1:200 
Ki67 Neomarkers RM-9106-S1 IF-P 1:200 
Smooth muscle actin Sigma C6198 IF-P, IF-F 1:400 
Streptavidin, Alexa 
Fluor 555-conjugate 
Invitrogen S32355 IF-F 1:500 
 
 
 
5.7.4 Microscopy 
 
All microscopy work was done in collaboration with Dr. Andreas Birbach. 
Images were acquired on an Olympus AX470 microscope (Olympus, Vienna, 
Austria) equipped with F-View II (grayscale) and ColorViewII (color) digital 
cameras using the manufacturer’s software (CellP; Olympus) and appropriate 
filter settings for fluorescence. 
 
 
 
 
 
Table 6: List of antibodies used for various stainings; Abbreviations: IF…Immunofluorescence, 
IHC…Immunohistochemistry, F…frozen sections, P…paraffin sections:  
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5.8 Statistical Analysis 
 
Statistical significance was determined by using one – way analysis of variance. 
P < 0,05 was considered significant. Error bars in figures represent SEM. 
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7 Discussion 
 
As prostate cancer is one of the most frequently diagnosed cancers in males 
and is also one of the leading causes of cancer related deaths we wanted to 
shed some light upon the development of this disease. While certain aspects of 
the development of prostate cancer are thoroughly described the correlation of 
inflammation and prostate cancer is far from understood. Therefore we wanted 
to study the effects of a permanent inflammatory signaling on prostate cancer 
progression. To this end we analyzed changes in morphology and gene 
expression in mice featuring both a constitutively active inflammatory signaling 
and a heterozygous knock out of a tumor suppressor known to play an 
important role in prostate cancer (PTEN+/-IKK2ca/ca) and compared them to 
wildtype and PTEN+/- mice. 
Permanent NFκB signaling through the constitutive activation of the key 
mediator IKK2 alone did not lead to any striking changes in gene expression or 
morphology. Therefore we conclude that a constitutive active inflammatory 
signaling is not enough to transform the prostate tissue in this mouse model. 
The exact reasons for this are open for speculation but it is an interesting 
finding because IKK2 has been shown to act as an oncogenic kinase in the past 
and its activation on a PTEN+/ background produces a clear phenotype. One 
possible explanation could be that NFκB is only able to activate certain 
promotors in a proliferating epithelium but not in a quiescent epithelium such as 
the one found in the prostate. This hypothesis is backed up by data we obtained 
from studying mice that feature the same genetic alterations in keratinocytes of 
the skin instead of the prostate but show a clear phenotype. (Birbach et al. 
unpublished)  
 
  
- 67 - 
 
As already mentioned above, the activation of IKK2 on a PTEN+/- background 
leads to a drastic change in both morphology and gene expression. We could 
show that several cytokines, such as TNFα and chemokines, such as CXCL2, 
CXCL5, CXCL10 and CXCL15 are upregulated in PTEN+/-IKK2ca/ca mice 
compared to wildtype and PTEN+/- mice. 
Moreover, histological stainings with certain antibodies (F4/80, CD11b, Gr-1) 
clearly demonstrate that there is a strong influx of immune cells, such as 
granulocytes, macrophages and monocytes into the prostatic tissue. These 
immune cells seem to be attracted by the aforementioned chemokines of the 
epithelium and cytokine – activated stroma. This is supported by the fact that 
the stimulation of PE-PTEN+/-IKK2ca/ca stromal cells with TNFα leads to an 
increased production of chemokines known to exert immune cell attracting 
functions. 
Furthermore, we could show that the development of the severe hyperplasia we 
observed in the double transgenic mice is the result of increased proliferation 
and not apoptosis. 
Another very interesting finding was that smooth muscle actin and myosin 
heavy chain 11 are drastically downregulated in PTEN+/-IKK2ca/ca mice, which 
clearly leads to the loss of smooth muscle cells which is a known finding in 
prostate cancer. We could confirm this by histological stainings showing a 
fading amount of smooth muscle around the epithelium. Interestingly however, 
PTEN+/-IKK2ca/ca mice did not develop an invasive phenotype at any time in 
their life. It is also important to note that the downregulation of smooth muscle 
markers is frequently associated with human prostate carcinoma. However, our 
results show that the loss of smooth muscle alone is not enough for a tumor to 
become invasive. 
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Inflammation and prostate cancer are undoubtedly interconnected on several 
levels. Although we did not observe the development of an invasive phenotype 
in our mouse model it might be very well possible that invasiveness occurs later 
in mouse life, succeeding additional mutations and alterations caused by 
persisting inflammatory signaling. Our results provide some evidence on how 
prostate cancer might be linked to inflammation. However, there is still a lot of 
work to be done to finally be able to understand this complex mechanism and 
come up with therapies or prophylaxes for the treatment of this unforgiving 
disease. 
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8 Appendage 
 
8.1 Abbreviations 
 
AID Activation - Induced cytidine Deaminase 
AP-1 Activator Protein 1 
AR Androgen Receptor 
BPH Benign Prostatic Hyperplasia 
ca constitutively active 
cDNA complementary DNA 
Ck Cytokeratin 
Col Collagen 
COX Cyclooxygenase 
CRE Cyclization Recombination 
CXCL CXC Ligand 
DHT Dihydrotestosterone 
DNA Deoxyribonucleic Acid 
EMT Epithelial - Mesenchymal Transition 
ER Endoplasmic Reticulum 
gDNA genomic DNA 
HCl Hydrogen Chloride 
HGPIN High - Grade prostate Intraepithelial neoplasia 
HIF Hypoxia Inducible Factor 
HPRT Hypoxanthine-guanine Phosphoribosyltransferase 
IF Immunofluoresence 
IHC Immunohistochemistry 
IKK IκB Kinase 
IL Interleukin 
IκB Inhibitor of κB 
MYC myelocytomatosis oncogene 
MYH11 Myosin Heavy Chain 11 
NaCl Sodium Chloride 
NFκB Nuclear Factor κB 
PB Probasin 
PBS Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
PIA Proliferative Inflammatory Atropy 
PIN Prostate Intraepithelial Neoplasia 
PKB Protein Kinase B 
PPM1A Protein Phosphatase 1A gene 
pRB Retinoblastoma Protein 
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PSA Prostate Specific Antigen 
PTEN Phosphatase and Tensin Homolog 
RAS RAt Sarcoma oncogene 
RNA Ribonucleic Acid 
RNI Reactive Nitrogen Intermediates 
ROS Reactive Oxygen Species 
RT - PCR  Reverse Transcriptase - PCR 
SEM Standard Error of the Mean 
SMA Smooth Muscle Actin 
SMAD Mothers Against Decapentaplegic gene family 
STAT Signal Transducer and Activator of Transcription 
TAM Tumor Associated Macrophage 
TGF Transforming Growth Factor 
TNF Tumor Necrosis Factor 
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